Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
publishDate:"[2020 TO 2029]"
collection:"CTG"
topic_facet:"Neoplasms, Plasma Cell"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=publishDate%3A%22%5B2020+TO+2029%5D%22&filter%5B%5D=collection%3A%22CTG%22&filter%5B%5D=topic_facet%3A%22Neoplasms%2C+Plasma+Cell%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields
/vufind/Search/Results?filter%5B%5D=publishDate%3A%22%5B2020+TO+2029%5D%22&filter%5B%5D=collection%3A%22CTG%22&filter%5B%5D=topic_facet%3A%22Neoplasms%2C+Plasma+Cell%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields
Search /vufind/Search2/Results?filter%5B%5D=publishDate%3A%22%5B2020+TO+2029%5D%22&filter%5B%5D=collection%3A%22CTG%22&filter%5B%5D=topic_facet%3A%22Neoplasms%2C+Plasma+Cell%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields
PubPharm (582)
1
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM : An Open-Label, Single Arm, Phase 2a Study of Bortezomib, Lenalidomide, Dexamethasone and Elotuzumab in Newly Diagnosed Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
2
Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone : A Phase 2 Study of CC220 (Iberdomide) Combined With Low-dose Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IberCd): ICON Study
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
3
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) : A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
4
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment : A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
5
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) : A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
6
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) : A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
7
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma : Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
8
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma : Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma A University of California Hematologic Malignancies Consortium Protocol (UCHMC1809)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
9
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma : A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects With Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
10
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma : A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[59]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Filter aufheben
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Erscheinungsjahr: 2020-2029
Filter aufheben
Thema: Neoplasms, Plasma Cell
Medienart
582
Aufsätze
582
E-Artikel
582
E-Ressourcen
Zeitschriftentitel
582
ClinicalTrials.gov
Thema
582
610
582
Multiple Myeloma
Neoplasms, Plasma Cell
557
Study Type: Interventional
229
Phase: Phase 2
173
Recruitment Status: Active, not recruiting
155
Recruitment Status: Recruiting
150
Recruitment Status: Completed
120
Phase: Phase 3
96
Medical Condition: Multiple Myeloma
93
Phase: Phase 1
83
Phase: Phase 1, Phase 2
56
Recruitment Status: Terminated
28
Recruitment Status: Not yet recruiting
21
Study Type: Observational
19
Smoldering Multiple Myeloma
14
Phase: Phase 1/Phase 2
14
Recruitment Status: Withdrawn
14
Recurrence
9
Phase: Phase 4
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
2020-
186
2024
217
2023
72
2022
53
2021
54
2020
Alle anzeigen ...
weniger ...
Erscheinungsjahr(e)
Von:
Bis:
Sprache
582
Englisch
Haven't found what you're looking for?
Wird geladen...